Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 9.30% | Add +1.8% | 404,505 | $81.10 | $33M | +7,000 | −$3M |
| STXS - Stereotaxis | 6.83% | Hold | 13,680,554 | $1.76 | $24M | — | — |
| RVMD - Revolution Medicines | 6.58% | Add +4.0% | 656,176 | $35.36 | $23M | +25,000 | −$4M |
| Merus | 5.51% | Add +2.2% | 461,804 | $42.09 | $19M | +10,000 | +$439K |
| ATRC - Atricure | 5.42% | Reduce −7.7% | 592,273 | $32.26 | $19M | −49,400 | −$503K |
| CYTK - Cytokinetics | 4.54% | Hold | 398,100 | $40.19 | $16M | — | — |
| Blueprint Medicines | 3.82% | Add +1.7% | 152,263 | $88.51 | $13M | +2,500 | +$414K |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.72% | Hold | 102,500 | $127.90 | $13M | — | — |
| AXGN - Axogen | 3.57% | Reduce −19.6% | 680,782 | $18.50 | $13M | −166,100 | −$1M |
| ASND - Ascendis Pharma A/S | 3.55% | Reduce −22.2% | 80,398 | $155.86 | $13M | −22,957 | −$2M |
| IDYA - Ideaya Biosciences | 2.74% | Add +18.1% | 589,330 | $16.38 | $10M | +90,503 | −$3M |
| XENE - Xenon Pharmaceuticals | 2.60% | Hold | 273,739 | $33.55 | $9M | — | — |
| Kalvista Pharmaceuticals | 2.46% | Reduce −7.3% | 752,359 | $11.54 | $9M | −59,319 | +$2M |
| NBIX - Neurocrine Biosciences | 2.25% | Hold | 71,615 | $110.60 | $8M | — | — |
| SNDX - Syndax Pharmaceuticals | 1.90% | Add +0.5% | 544,502 | $12.28 | $7M | +2,500 | −$476K |
| DAWNGBX — | 1.64% | Hold | 731,363 | $7.93 | $6M | — | — |
| TNDM - Tandem Diabetes Care | 1.60% | Add +31.8% | 294,208 | $19.16 | $6M | +71,000 | −$2M |
| URGN - Urogen Pharma | 1.54% | Hold | 492,515 | $11.06 | $5M | — | — |
| BHVN - Biohaven | 1.50% | Hold | 220,235 | $24.04 | $5M | — | — |
| MLYS - Mineralys Therapeutics | 1.39% | Add +111.1% | 309,200 | $15.88 | $5M | +162,700 | +$3M |
| RCUS - Arcus Biosciences | 1.39% | Add +145.9% | 625,126 | $7.85 | $5M | +370,909 | +$1M |
| DXCM - Dexcom | 1.27% | Hold | 65,552 | $68.29 | $4M | — | — |
| BCRX - Biocryst Pharmaceuticals | 1.19% | Reduce −16.3% | 558,255 | $7.50 | $4M | −108,745 | −$829K |
| EWTX - Edgewise Therapeutics | 1.14% | Reduce −2.1% | 183,140 | $22.00 | $4M | −4,000 | −$968K |
| LKFT - Galapagos | 0.93% | Hold | 130,175 | $25.12 | $3M | — | — |
| INGN - Inogen | 0.93% | Add +119.4% | 458,065 | $7.13 | $3M | +249,275 | +$1M |
| PODD - Insulet | 0.89% | Reduce −4.0% | 11,900 | $262.61 | $3M | −500 | −$112K |
| ALKS - Alkermes | 0.88% | Reduce −22.0% | 94,200 | $33.02 | $3M | −26,500 | −$361K |
| KURA - Kura Oncology | 0.87% | Add +3.3% | 463,368 | $6.60 | $3M | +15,000 | −$847K |
| STOK - Stoke Therapeutics | 0.84% | Add +159.5% | 443,998 | $6.65 | $3M | +272,901 | +$1M |
| IMVT - Immunovant | 0.82% | Add +57.4% | 169,996 | $17.09 | $3M | +62,000 | +$230K |
| BCAX - Bicara Therapeutics | 0.78% | Add +100.9% | 212,001 | $13.03 | $3M | +106,501 | +$925K |
| ARAY - Accuray | 0.62% | Hold | 1,222,358 | $1.79 | $2M | — | — |
| 2seventy Bio | 0.60% | Hold | 429,252 | $4.94 | $2M | — | — |
| PRQR - Proqr Therapeutics | 0.59% | Hold | 1,567,561 | $1.33 | $2M | — | — |
| CMPS - Compass Pathways | 0.58% | Add +192.4% | 711,046 | $2.86 | $2M | +467,836 | +$1M |
| ALLO - Allogene Therapeutics | 0.57% | Add +11.3% | 1,380,118 | $1.46 | $2M | +140,000 | −$626K |
| TELA - Tela Bio | 0.50% | Hold | 1,441,029 | $1.22 | $2M | — | — |
| ALGN - Align Technology | 0.50% | Add +100.0% | 11,000 | $158.86 | $2M | +5,500 | +$601K |
| DNLI - Denali Therapeutics | 0.49% | New | 127,900 | $13.60 | $2M | +127,900 | +$2M |
| CATBUSD - Astria Therapeutics | 0.48% | Add +5.0% | 314,775 | $5.34 | $2M | +15,000 | −$999K |
| VKTX - Viking Therapeutics | 0.44% | Hold | 64,516 | $24.15 | $2M | — | — |
| Regulus Therapeutics | 0.42% | Reduce −3.2% | 847,176 | $1.75 | $1M | −28,024 | +$100K |
| BWAY - Brainsway | 0.42% | Reduce −19.0% | 156,533 | $9.47 | $1M | −36,675 | −$340K |
| ORIC - Oric Pharmaceuticals | 0.38% | New | 242,000 | $5.58 | $1M | +242,000 | +$1M |
| Keros Therapeutics | 0.38% | Hold | 130,316 | $10.19 | $1M | — | — |
| LXEO - Lexeo Therapeutics | 0.37% | Reduce −3.8% | 378,083 | $3.47 | $1M | −15,000 | −$1M |
| Iteos Therapeutics | 0.36% | Add +13.3% | 213,347 | $5.97 | $1M | +25,000 | −$173K |
| PVLA - Palvella Therapeutics | 0.34% | Reduce −39.3% | 43,348 | $27.99 | $1M | −28,104 | +$356K |
| SPRY - Ars Pharmaceuticals | 0.34% | Add +7.3% | 95,290 | $12.58 | $1M | +6,500 | +$262K |
| Holding | 0.32% | Hold | 2,511,374 | $0.4516 | $1M | — | — |
| ALEC - Alector | 0.32% | Hold | 912,928 | $1.23 | $1M | — | — |
| FHTX - Foghorn Therapeutics | 0.32% | Add +63.2% | 304,752 | $3.65 | $1M | +118,035 | +$231K |
| Immatics | 0.31% | Hold | 245,000 | $4.51 | $1M | — | — |
| GPCR - Structure Therapeutics | 0.29% | Add +66.2% | 59,000 | $17.31 | $1M | +23,500 | +$59K |
| Vyne Therapeutics | 0.28% | New | 636,103 | $1.58 | $1M | +636,103 | +$1M |
| Mediwound | 0.28% | Hold | 64,479 | $15.52 | $1M | — | — |
| Gossamer Bio | 0.28% | Reduce −35.6% | 907,854 | $1.10 | $999K | −501,408 | −$276K |
| BNTX - Biontech Se | 0.27% | Add +23.5% | 10,500 | $91.06 | $956K | +2,000 | −$12K |
| AUTL - Autolus Therapeutics | 0.26% | Hold | 586,667 | $1.55 | $909K | — | — |
| Sage Therapeutics | 0.24% | Hold | 108,200 | $7.95 | $860K | — | — |
| Korro Bio | 0.23% | New | 47,086 | $17.41 | $820K | +47,086 | +$820K |
| IPSC - Century Therapeutics | 0.23% | Hold | 1,704,232 | $0.4760 | $811K | — | — |
| LRMR - Larimar Therapeutics | 0.23% | Hold | 371,434 | $2.15 | $799K | — | — |
| Polypid | 0.22% | Hold | 291,273 | $2.71 | $789K | — | — |
| TSHA - Taysha Gene Therapies | 0.21% | Hold | 522,500 | $1.39 | $726K | — | — |
| BCYC - Bicycle Therapeutics | 0.19% | Reduce −33.1% | 80,799 | $8.49 | $686K | −40,000 | −$1M |
| NGNE - Neurogene | 0.17% | Hold | 51,500 | $11.71 | $603K | — | — |
| CRDF - Cardiff Oncology | 0.13% | New | 150,000 | $3.14 | $471K | +150,000 | +$471K |
| ERAS - Erasca | 0.13% | New | 340,000 | $1.37 | $466K | +340,000 | +$466K |
| IFRX - Inflarx | 0.13% | New | 450,000 | $1.02 | $459K | +450,000 | +$459K |
| Adicet Bio | 0.13% | Hold | 600,000 | $0.7550 | $453K | — | — |
| AQST - Aquestive Therapeutics | 0.12% | Add +11.8% | 142,000 | $2.90 | $412K | +15,000 | −$40K |
| Compugen | 0.11% | Reduce −39.1% | 272,402 | $1.46 | $398K | −174,800 | −$287K |
| ADCT - Adc Therapeutics SA | 0.09% | Hold | 224,081 | $1.41 | $316K | — | — |
| Sutro Biopharma | 0.08% | Hold | 437,079 | $0.6506 | $284K | — | — |
| APRE - Aprea Therapeutics | 0.08% | Hold | 137,174 | $2.04 | $280K | — | — |
| Biomx | 0.06% | Hold | 401,136 | $0.5557 | $223K | — | — |
| Nevro | 0.06% | Hold | 38,000 | $5.84 | $222K | — | — |
| BDTX — | 0.06% | Hold | 140,000 | $1.55 | $217K | — | — |
| Spero Therapeutics | 0.03% | Hold | 125,000 | $0.7200 | $90K | — | — |
| Tenaya Therapeutics | 0.01% | New | 47,319 | $0.5701 | $27K | +47,319 | +$27K |
Showing top 50 of 82 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| CNTA - Centessa Pharmaceuticals | 0.20% | Exit | 0 | $16.75 | $795K | −47,453 | −$795K |
| VIR - Vir Biotechnology | 0.19% | Exit | 0 | $7.34 | $734K | −100,000 | −$734K |
| ACRV - Acrivon Therapeutics | 0.17% | Exit | 0 | $6.02 | $677K | −112,414 | −$677K |
| Masimo | 0.13% | Exit | 0 | $165.33 | $496K | −3,000 | −$496K |
| CATX - Perspective Therapeutics | 0.11% | Exit | 0 | $3.19 | $415K | −130,169 | −$415K |
| Acelyrin | 0.07% | Exit | 0 | $3.14 | $276K | −87,989 | −$276K |
| CMPX - Compass Therapeutics | 0.06% | Exit | 0 | $1.45 | $230K | −158,394 | −$230K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2